FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
WATERTOWN, Mass., May 01, 2017 -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies that avoid unwanted immunogenicity for the treatment of rare and serious diseases, today announced several presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 10-13, 2017 at the Marriott Wardman Park Hotel in Washington, D.C.
Selecta co-founder Dr. Robert Langer will be the Plenary Speaker at ASGCT’s Presidential Symposium on Friday, May 12, 2017. Dr. Langer is an Institute Professor at the Massachusetts Institute of Technology who has over 1,100 issued and pending patents. He has earned numerous recognitions, including the US National Medal of Science, the US National Medal of Technology and Innovation, and the Queen Elizabeth Prize for Engineering. Among other topics, Dr. Langer is expected to discuss the need for repeat dosing in gene therapy. Selecta is working with various collaborators on two proprietary gene therapy programs that utilize Selecta’s Synthetic Vaccine Particles (SVP™) technology to enable repeat gene therapy doses.
Additional ASGCT presentations include:
Anc80 Mediates Hepatic Correction of Methylmalonyl-CoA Mutase Deficiency in Murine Models of Methymalonic Acidemia
| Type: | Poster | ||||||
| Date: | May 11, 2017 from 5:15-7:15 p.m. ET | ||||||
| Session: | Liver-Based Therapy for Genetic and Metabolic Disease | ||||||
| Abstract Number: | 404 | ||||||
| Location: | Exhibit Hall A & B South | ||||||
Modulation of AAV Vector Dosing and Avoidance of Capsid Immune Responses via Repeated Co-Administration of Vector with Rapamycin Tolerogenic Nanoparticles
| Type: | Oral | ||||||
| Date/Time: | May 12, 2017 at 4:45 p.m. ET | ||||||
| Session: | Immunological Aspects of Gene Therapy and Vaccines | ||||||
| Abstract Number: | 521 | ||||||
| Location: | Lincoln 2, 3, 4 | ||||||
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications. Selecta is applying its proprietary Synthetic Vaccine Particles (SVP™) to a range of therapeutic areas in which immunogenicity is a key challenge. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and reduce their debilitating symptoms, including flares and inflammatory arthritis. Further, Selecta’s two proprietary gene therapy product candidates have the potential to enable repeat administration, allowing for dose adjustment in patients and maintenance of therapeutic activity over time. The company is seeking to expand the use of its SVP platform in other areas, such as allergies, autoimmune diseases and vaccines. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com.
Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the development of its pipeline, the ability of the company’s SVP platform, including SVP-Rapamycin, to mitigate immune response and create better therapeutic outcomes, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 28, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.
Contact Information: Jason Fredette Selecta Biosciences, Inc. 617-231-8078 [email protected]
